Dalton WS - Search Results

1

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Dalton WS, et al. J Clin Oncol. 1989 Apr;7(4):415-24. doi: 10.1200/JCO.1989.7.4.415. J Clin Oncol. 1989. PMID: 2564428

2

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. List AF, et al. J Clin Oncol. 1993 Sep;11(9):1652-60. doi: 10.1200/JCO.1993.11.9.1652. J Clin Oncol. 1993. PMID: 8102639 Clinical Trial.

3

Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies.

Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, et al. Grogan T, et al. Lab Invest. 1990 Dec;63(6):815-24. Lab Invest. 1990. PMID: 1979362

4

Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model.

Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Lehnert M, et al. Among authors: dalton ws. Blood. 1991 Jan 15;77(2):348-54. Blood. 1991. PMID: 1670760 Free article.

5

Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.

Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Salmon SE, et al. Among authors: dalton ws. Blood. 1991 Jul 1;78(1):44-50. Blood. 1991. PMID: 1676918 Free article. Clinical Trial.

6

Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration.

Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Pennock GD, et al. Among authors: dalton ws. J Natl Cancer Inst. 1991 Jan 16;83(2):105-10. doi: 10.1093/jnci/83.2.105. J Natl Cancer Inst. 1991. PMID: 1988684

7

Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Dalton WS, et al. Blood. 1989 Feb 15;73(3):747-52. Blood. 1989. PMID: 2563664 Free article.

8

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.

Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Salmon SE, et al. Among authors: dalton ws. J Natl Cancer Inst. 1989 May 3;81(9):696-701. doi: 10.1093/jnci/81.9.696. J Natl Cancer Inst. 1989. PMID: 2565403

9

Reversal of drug-resistance in multiple myeloma with verapamil.

Durie BG, Dalton WS. Durie BG, et al. Among authors: dalton ws. Br J Haematol. 1988 Feb;68(2):203-6. doi: 10.1111/j.1365-2141.1988.tb06190.x. Br J Haematol. 1988. PMID: 3348977

10

Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.

Klimecki WT, Taylor CW, Dalton WS. Klimecki WT, et al. Among authors: dalton ws. J Clin Immunol. 1995 May;15(3):152-8. doi: 10.1007/BF01543107. J Clin Immunol. 1995. PMID: 7559918

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters